BACKGROUND: Testicular germ cell tumor (TGCT) incidence increased steadily in recent decades, but causes remain elusive. Germ cell function may be influenced by cannabinoids, and 2 prior epidemiologic studies reported that the use of marijuana may be associated with nonseminomatous TGCT. Here, the authors evaluate the relation between TGCTs and exposure to marijuana and other recreational drugs using a population-based case-control study. METHODS: In total, 163 patients who were diagnosed with TGCT in Los Angeles County from December 1986 to April 1991 were enrolled, and 292 controls were matched on age, race/ethnicity, and neighborhood. Participants were asked about drug use by a structured, in-person interview. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression analysis adjusted for history of cryptorchidism; education; religiosity; and reported use of marijuana, cocaine, and amyl nitrite. RESULTS: Compared with never use, ever use of marijuana had a 2-fold increased risk (OR, 1.94; 95% CI, 1.02-3.68), whereas ever use of cocaine had a negative association with TGCT (OR, 0.54; 95% CI, 0.32-0.91). Stratification on tumor histology revealed a specific association of marijuana use with nonseminoma and mixed histology tumors (OR, 2.42; 95% CI, 1.08-5.42). CONCLUSIONS: A specific association was observed between marijuana use and the risk of nonseminoma and mixed tumors. To the authors' knowledge, this is the first report of a negative association between cocaine use and TGCT risk. The current results warrant mechanistic studies of marijuana's effect on the endocannabinoid system and TGCT risk and caution that recreational and therapeutic use of cannabinoids by young men may confer malignant potential to testicular germ cells.
BACKGROUND: Testicular germ cell tumor (TGCT) incidence increased steadily in recent decades, but causes remain elusive. Germ cell function may be influenced by cannabinoids, and 2 prior epidemiologic studies reported that the use of marijuana may be associated with nonseminomatous TGCT. Here, the authors evaluate the relation between TGCTs and exposure to marijuana and other recreational drugs using a population-based case-control study. METHODS: In total, 163 patients who were diagnosed with TGCT in Los Angeles County from December 1986 to April 1991 were enrolled, and 292 controls were matched on age, race/ethnicity, and neighborhood. Participants were asked about drug use by a structured, in-person interview. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression analysis adjusted for history of cryptorchidism; education; religiosity; and reported use of marijuana, cocaine, and amyl nitrite. RESULTS: Compared with never use, ever use of marijuana had a 2-fold increased risk (OR, 1.94; 95% CI, 1.02-3.68), whereas ever use of cocaine had a negative association with TGCT (OR, 0.54; 95% CI, 0.32-0.91). Stratification on tumor histology revealed a specific association of marijuana use with nonseminoma and mixed histology tumors (OR, 2.42; 95% CI, 1.08-5.42). CONCLUSIONS: A specific association was observed between marijuana use and the risk of nonseminoma and mixed tumors. To the authors' knowledge, this is the first report of a negative association between cocaine use and TGCT risk. The current results warrant mechanistic studies of marijuana's effect on the endocannabinoid system and TGCT risk and caution that recreational and therapeutic use of cannabinoids by young men may confer malignant potential to testicular germ cells.
Authors: Grant Buchanan; Miao Yang; Albert Cheong; Jonathan M Harris; Ryan A Irvine; Paul F Lambert; Nicole L Moore; Michael Raynor; Petra J Neufing; Gerhard A Coetzee; Wayne D Tilley Journal: Hum Mol Genet Date: 2004-06-15 Impact factor: 6.150
Authors: Katherine A McGlynn; Sabah M Quraishi; Barry I Graubard; Jean-Philippe Weber; Mark V Rubertone; Ralph L Erickson Journal: J Natl Cancer Inst Date: 2008-04-29 Impact factor: 13.506
Authors: Rachel Linger; Darshna Dudakia; Robert Huddart; Kathy Tucker; Michael Friedlander; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Agnes Chompret; Dominique Stoppa-Lyonnet; Catherine Bonaïti-Pellié; Axel Heidenreich; Peter Albers; Edith Olah; Lajos Geczi; Istvan Bodrogi; Peter A Daly; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Sergei A Tjulandin; Ludmila Liubchenko; Hans Stoll; Walter Weber; Lawrence Einhorn; Mary McMaster; Larissa Korde; Mark H Greene; Katherine L Nathanson; Victoria Cortessis; Douglas F Easton; D Timothy Bishop; Michael R Stratton; Elizabeth A Rapley Journal: Genes Chromosomes Cancer Date: 2008-03 Impact factor: 5.006
Authors: Armen A Ghazarian; Scott P Kelly; Sean F Altekruse; Philip S Rosenberg; Katherine A McGlynn Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: Yu-Hui Jenny Huang; Zuo-Feng Zhang; Donald P Tashkin; Bingjian Feng; Kurt Straif; Mia Hashibe Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01 Impact factor: 4.254
Authors: Mary L Biggs; David R Doody; Britton Trabert; Jacqueline R Starr; Chu Chen; Stephen M Schwartz Journal: Int J Cancer Date: 2016-08-16 Impact factor: 7.396